Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹425 Cr
verified against source
Revenue YoY
23.6%
reported change
EBITDA
₹401 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Metropolis Healthcare delivered a strong FY26 with group revenue of ₹1,646 crore (+23.6% YoY) and EBITDA margin of 24.4%. Organic revenue grew 13.7% YoY, exceeding the 12-13% guidance, driven by patient volume growth of 7.5% and realization improvement. Organic EBITDA margin expanded 140 bps to 25.9%, aided by lab platform upgrades, vendor consolidation, and operating leverage. The core diagnostics acquisition achieved high single-digit EBITDA margin within four quarters, on track for 20%+ in three years. Management guided for 14-15% organic revenue growth and 27-28% group EBITDA margin over the next three years, supported by network productivity gains, specialty mix improvement, and digital channel expansion. Key risks include competitive intensity in tier-1 cities and potential integration challenges from future M&A.
Colored figures show movement against the previous available record.
Guidance to track
- Driven by 8-9% patient volume growth and ~5% realization improvement, with potential price increases.
- Supported by operating leverage, productivity gains, and core diagnostics reaching 20%+ margin.
- Management expects EBITDA margin expansion of 125-150 bps in the coming fiscal year.
- Expand asset-light network and upgrade centers to include basic radiology, targeting center-to-lab ratio of 35:1.
Risks flagged
- Growth in tier-1 cities like Mumbai is around 11-14%, potentially constrained by high competition from organized and unorganized players.
- While current acquisitions are on track, future deals may face quality and integration challenges, as management noted many assets do not meet their standards.
- Management indicated no price hike planned currently, but realization growth partly relies on future price increases, which may not materialize if competitive pressures persist.
Key quotes
- We are not looking at a price increase, but as the things progresses during the year, if there is a need for us to do it, we would not hesitate to do it.
- We believe a sustainable EBITDA at this point over the next three years of 27 to 28% makes sense for us and if we are able to generate more operating leverage we would like to invest it back in the business.
- Our lab addition phase is over... we are not planning to add a high number of labs in the network.
Research modules